YouTube · Q2 FY2026 · 2026-05-27
IQV · NYSE
IQVIA Holdings Inc.
Diagnostics & Research · United States
USD 272.902.6% daily changeQuote 2026-10-06 · USD
- Market cap (USD)
- US$44.92B
- Trailing P/E
- 33.90x
- Forward P/E
- 18.88x
- Quarterly revenue growth
- 8.7%
- Trailing net margin
- 8.1%
- Indicated dividend yield
- —
Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-27 (provider estimate, not issuer-confirmed).
Company background
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Company websiteQ2 2026
Go beyond the headline.
IQVIA (IQV): Best Bookings Since 2022, Stock +14% — and GAAP Profit Did Not Move. Is IQV a Buy?
Published 2026-08-02
Comparable businesses
IQV peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | IQVIQVIA Holdings Inc.Snapshot 2026-10-06Financial period: 2026-06-30 | AAgilent Technologies, Inc.Snapshot 2026-10-06Financial period: 2026-07-31 | ILMNIllumina, Inc.Snapshot 2026-10-06Financial period: 2026-06-28 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$44.92B | US$49.42B | US$45.67B | US$47.55Bn=2 |
| Forward P/EProvider forward earnings estimate | 18.88x | 25.94x | 49.54x | 37.74xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 19.06x | 24.37x | 39.57x | 31.97xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | 8.7% | 8.1% | 9.4% | 8.8%n=2 |
| Operating marginLatest reported quarter | 13.0% | 25.6% | 21.1% | 23.3%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 4.8% | 2.1% | 1.7% | 1.9%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 4.65x | 1.15x | 1.18x | 1.16xn=2 |
| Debt / equityTotal debt / positive book equity | 2.58x | 0.56x | 0.89x | 0.73xn=2 |
| Trailing P/ETrailing twelve-month earnings | 33.90x | 34.57x | 56.43x | 45.50xn=2 |
| Price / bookPrice / positive book equity per share | 7.28x | 6.71x | 16.09x | 11.40xn=2 |
| EV / salesEnterprise value / trailing revenue | 3.42x | 6.88x | 10.17x | 8.52xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | -0.6% | 8.5% | -9.4% | -0.5%n=2 |
| Gross marginTrailing twelve months | 33.0% | 53.6% | 67.9% | 60.8%n=2 |
| Net marginTrailing twelve months | 8.1% | 19.5% | 18.3% | 18.9%n=2 |
| Return on equityProvider trailing return; positive equity only | 22.8% | 21.0% | 32.3% | 26.7%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | 12.7% | 14.4% | 17.7% | 16.1%n=2 |
| Dividend yieldIndicated annual dividend / price | — | 0.6% | — | — |
| Earnings payoutProvider trailing dividend payout | 0.0% | 20.0% | 0.0% | 10.0%n=2 |
| Current ratioCurrent assets / current liabilities | 0.71x | 2.05x | 1.80x | 1.92xn=2 |
| BetaProvider historical market sensitivity | 1.17 | 1.21 | 1.42 | 1.31n=2 |
YouTube · Q2 FY2026 · 2026-05-27
YouTube · Q2 2026 · 2026-07-31
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for IQV
Q2 20262026-08-02
IQVIA (IQV): Best Bookings Since 2022, Stock +14% — and GAAP Profit Did Not Move. Is IQV a Buy?
Presentation · 2026-08-02 · YouTube
Q1 20262026-05-05
IQV Stock: $4.2B Revenue — Q1 2026 Earnings Analysis
Presentation · 2026-05-05 · YouTube